RedHill Biopharma Ltd. (RDHL)
| Market Cap | 6.28M |
| Revenue (ttm) | 61.80M |
| Net Income (ttm) | -71.67M |
| Shares Out | 2.95M |
| EPS (ttm) | -48.00 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 42,655 |
| Open | 2.16 |
| Previous Close | 2.20 |
| Day's Range | 2.09 - 2.32 |
| 52-Week Range | 2.04 - 49.20 |
| Beta | 2.15 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Jun 22, 2023 |
About RDHL
RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company promotes gastrointestinal drugs, including Movantik for opioid-induced constipation in adults with chronic non-cancer pain; Talicia for the treatment of Helicobacter pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its clinical late-stage investigational development programs include RHB-204, which is in Phase 3 study for pulmonary nontuberculous mycobacteria infectio... [Read more]
Full Company ProfileFinancial Performance
In 2022, RDHL's revenue was $61.80 million, a decrease of -27.94% compared to the previous year's $85.76 million. Losses were -$71.67 million, -26.68% less than in 2021.
Financial StatementsNews
RedHill Provides R&D Update
RedHill has elected to terminate RHB-204's U.S. Phase 3 study for Non-tuberculosis Mycobacteria (NTM) disease due to low accrual rate and plans to shift resources to more rapidly advance RHB-107 late-...
RedHill Biopharma Receives NASDAQ Notification Regarding Minimum Market Value of Publicly Held Shares Deficiency
TEL AVIV, Israel and RALEIGH, N.C. , May 15, 2023 /PRNewswire/ -- RedHill Biopharma Ltd.
RedHill Publishes New Talicia® Data on Generic Non-Bioequivalence in AP&T and Presents New Dosing Data at Digestive Disease Week
New Talicia PBPK modeling data, published in AP&T Journal, showed that generically substituted regimens are non-bioequivalent to Talicia Separately, new Talicia PBPK modeling data, presented at DDW, s...
RedHill's RHB-102 (BEKINDA®) and Opaganib Granted New Patents in Oncology Setting
European Patent Office grants RHB-102 patent covering antiemetic extended-release solid dosage forms for the prevention of nausea and vomiting (CINV/RINV), providing protection of RHB-102 to March 203...
RedHill Biopharma Announces Q4/22 & Full-Year 2022 Results and Operational Highlights
Having extinguished all debt and significantly reduced cost-base, RedHill is now focused on late-stage pipeline advancement, in collaboration with U.S. and other governments, commercial growth and rev...
RedHill Biopharma Regains Compliance with Nasdaq Minimum Bid Price Requirement
TEL AVIV, Israel & RALEIGH, N.C. , April 11, 2023 /PRNewswire/ -- RedHill Biopharma Ltd.
RedHill Biopharma Announces Closing of $6 Million Registered Direct Offering
TEL AVIV, Israel and RALEIGH, N.C. , April 3, 2023 /PRNewswire/ -- RedHill Biopharma Ltd.
RedHill Biopharma Announces $6 Million Registered Direct Offering
TEL AVIV, Israel and RALEIGH, N.C. , March 30, 2023 /PRNewswire/ -- RedHill Biopharma Ltd.
RedHill Initiates First Community-Setting Warranty Program to Refund Talicia Non-Responders
RedHill commits to reimburse out-of-pocket costs for Talicia patients that complete the full 14-day treatment course and whose infection is not eradicated based on post-treatment confirmation testing ...
RedHill Biopharma Announces Plan to Implement ADS Ratio Change
TEL AVIV, Israel and RALEIGH, NC , March 16, 2023 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that it pla...
RedHill Biopharma Announces Definitive Agreement for Up To $6 Million Private Placement with a Single Investor
TEL AVIV, Israel and RALEIGH, NC , March 8, 2023 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced agreement, ...
RedHill Biopharma Ltd Announces RDHL Opaganib Selected by NIH RNCP For Development
RedHill's Opaganib Selected by the NIH Radiation and Nuclear Countermeasures Program The National Institutes of Health's (NIH) Radiation and Nuclear Countermeasures Program (RNCP) has selected opagani...
RedHill's Opaganib Selected by the NIH Radiation and Nuclear Countermeasures Program
The National Institutes of Health's (NIH) Radiation and Nuclear Countermeasures Program (RNCP) has selected opaganib for testing via their radiation medical countermeasures Product Development Support...
RedHill Biopharma Ltd Announces RedHill's RHB-102 Positive MHRA Meeting & MAA Plan
RedHill Announces Positive MHRA Meeting and Planned UK Marketing Authorisation Application of RHB-102 (BEKINDA®) for Oncology Support UK MHRA scientific advice meeting deems RHB-102 (BEKINDA®) data su...
RedHill Announces Positive MHRA Meeting and Planned UK Marketing Authorisation Application of RHB-102 (BEKINDA®) for Oncology Support
UK MHRA scientific advice meeting deems RHB-102 (BEKINDA ®) data supportive of submission for approval for chemotherapy and radiotherapy induced nausea and vomiting (CINV/RINV) RHB-102 UK Marketing A...
RedHill Biopharma Announces Positive FDA Meeting Regarding Opaganib for Acute Nuclear Radiation Syndrome
FDA provided guidance on opaganib's regulatory pathway under the Animal Rule for Acute Radiation Syndrome (ARS) The FDA's Animal Rule allows for the use of pivotal animal model efficacy studies to sup...
RedHill Biopharma and HealthCare Royalty Agree to Extinguish All RedHill's Debt Obligations in Exchange for Movantik®
TEL AVIV, Israel and RALEIGH, N.C , Feb. 6, 2023 /PRNewswire/ -- RedHill Biopharma Ltd. (NASDAQ: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced the extingui...
RedHill Receives USPTO Notice of Allowance for a Patent Covering Phase 3-stage RHB-204 for the Treatment of NTM Disease
Once issued, the patent is expected to extend protection of RHB-204 to 2041 RHB-204 is currently undergoing a Phase 3 study in the U.S. as the first stand-alone standard of care first-line drug candid...
RedHill Announces Publication of Positive Phase 2 Study Results with Once-Daily Oral RHB-107 in Non-Hospitalized COVID-19
Positive data from a U.S. Phase 2 study of once-daily oral RHB-107 (upamostat) in symptomatic COVID-19 published in the peer-reviewed International Journal of Infectious Diseases RHB-107 successfully ...
Aegis Capital Corp. Acted as Sole Bookrunner on an $8 Million Underwritten Public Offering for RedHill Biopharma Ltd. (NASDAQ:RDHL)
NEW YORK, NY / ACCESSWIRE / December 7, 2022 / Aegis Capital Corp. acted as Sole Bookrunner on an $8 Million Underwritten Public Offering for RedHill Biopharma Ltd. (NASDAQ:RDHL).
RedHill Biopharma Closes $8.0 Million Underwritten Public Offering
TEL AVIV, Israel and RALEIGH, N.C. , Dec. 6, 2022 /PRNewswire/ -- RedHill Biopharma Ltd.
RedHill Biopharma Prices $8.0 Million Underwritten Public Offering
TEL AVIV, Israel, and RALEIGH, N.C. , Dec. 2, 2022 /PRNewswire/ -- RedHill Biopharma Ltd.
RedHill Biopharma Announces Proposed Public Offering
TEL AVIV, Israel and RALEIGH, N.C. , Dec. 1, 2022 /PRNewswire/ -- RedHill Biopharma Ltd.
RedHill Biopharma Announces Q3/22 Results and Operational Highlights
Non-binding agreement in principle reached with HCR on sale of Movantik to extinguish all debt obligations, to facilitate growth Q3/22 Net revenues of $17.6 million; Operating loss of $7.1 million; Q3...
RedHill Biopharma Announces Positive New Data with Opaganib for Nuclear Radiation Injury
Positive in vivo results from a new study of opaganib in radiation-induced hematologic and renal toxicity reaffirms opaganib's potential protective impact on hematological and kidney function followin...